Emerging role of nivolumab in the management of patients with non-small-cell lung cancer: current data and future perspectives

Abstract

Immune-checkpoint inhibitors have become valuable therapies in the treatment of patients with non-small-cell lung cancer (NSCLC). Recent clinical trials have shown promising results with regard to efficacy and toxicity profiles of these agents compared to cytotoxic chemotherapy. Nivolumab was one of the first immune-checkpoint inhibitors to demonstrate clinical activity in patients with NSCLC, and is currently approved in the US for treatment of patients with advanced squamous and nonsquamous NSCLC who have progressed on or after platinum-based chemotherapy. This review provides an update on nivolumab’s pharmacology, safety, and efficacy, as established by the CheckMate trials. We also discuss specific applications and strategies for the use of nivolumab in NSCLC patients, as well as predictive biomarkers and their role in treatment selection.

Keywords:

• nivolumab
• non-small-cell lung cancer
• immune-checkpoint inhibitor
• PD1

Disclosure

LH consults for AbbVie, Lilly, Genentech, Merck, Bristol-Myers Squibb, Boehringer Ingelheim, Xcovery, and EMD Serono. EF reports no conflicts of interest in this work.